Fluidiconic Biotechnology -- MedSelect

 

Category: Biotech Service

Exhibitor: NATIONAL TSING HUA UNIVERSITY

Booth No: N315A

 

Characteristic

 

**Characteristic**
Fluidiconic Biotechnology offers a comprehensive Tumor-Microenvironment-on-Chip and automated culture analysis platform to help pharmaceutical companies, CROs, and research institutions accelerate and enhance the precision of cancer drug development. Our core chip products: TMoC series biochips simulate the molecular gradient environment within tumors—from the perivascular region to the core—highly preserve tumor genotypes, cellular composition, and drug response characteristics. TMoC-Lite chip supports high-throughput screening; the advanced TMoC-Pro chip emulates complex tumor features such as angiogenesis and fibrosis.
With our MedSelect series platforms, users can perform dynamic single-chip culture (MedSelect Core) and automated high-throughput dynamic culture and realtime imaging (MedSelect Ultra), integrated with analysis software (BioVision) for in-depth visualization and report generation. BioLab platform supports customized chip integration and ODM services, helping early-stage developers quickly build complete dynamic culture systems.
We are committed to creating an ex vivo testing platform tailored to future cancer drug development needs, enhancing throughput, data interpretation, and clinical translation efficiency.

**R & D team/Company Profile**
Fluidiconic Biotechnology originated from National Tsing Hua University, founded under the guidance of Professor Jhen-Huang Huang and led by Dr. Hsuan-Yu Mu. The team focuses on developing the cancer drug evaluation platform, MedSelect, which uses dynamic 3D culture on microfluidic chips to simulate the real tumor microenvironment. The goal is to address the high cost, low accuracy, and ethical concerns associated with traditional animal testing.
Their core technology has been published in international journals and recognized with the National Innovation Award&Future Tech Award. The team brings together expertise in chemical engineering, biomedical science, microfluidics, and business operations, specializing in tumor microenvironment simulation and immunotherapy efficacy analysis. By integrating academic strength with practical commercialization experience, Fluidiconic Biotechnology aims to become a leading standard in preclinical cancer efficacy validation.

**Contact window**
Steven Mu
+886 911300283
fluidiconic@fcbio.net

 

Other Products

 

• 

  Boron Drug Technology -- Key technologies for the development of lung-targeted boron drugs

• 

  Cell3Solutions Co., Ltd.-- High-Throughput Microfluidic XY Swine Sperm Sorting

• 

  JelloX Biotech Inc. -- 3D Thick Tissue Automated Staining

• 

  Prof. Tsai-Te Lu -- Development of Advanced Corneal Storage Media and Stem Culture Media for Optimizing Clinical Transplantation

• 

  Prof.Chien-Wen Jeff Chang -- Integrated Platform for Stem Cell Engineering & Matrix-Based Delivery

• 

  Prof. Chi-Shuo Chen -- Neubrix™ Exosome Pulmonary Precision Aerosolization Therapy

• 

  Prof. Kun-Hua Lee -- Kickstart: A Novel Digital Therapeutic System for Craving Assessment in Addiction Treatment

• 

  Prof. Ting-Wei Wang -- Lightweight Flexible Electromagnetic Patch for Non-contact Health Monitoring

 

 

 

Back